{"schema_version":"secwatch.filing_event.v1","accession":"0001062993-26-001567","form_type":"8-K","ticker":"INM","cik":"0001728328","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2026-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.018661+00:00","generated_at":"2026-05-15T09:22:49.916767+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"InMed reports positive INM-901 data in human brain organoid neuroinflammation models","bullets":["INM-901 reduced neuroinflammation in 3D human brain organoid models of Alzheimer's disease.","Dose-dependent reduction of pro-inflammatory markers IL-6 and IL-8 observed in two distinct organoid models.","Company targets pre-IND meeting with FDA in Q3 2026 and Phase 1 trial start in 2027.","Prior studies showed reduction of inflammatory biomarkers in in vivo Alzheimer's and ex vivo LPS models.","Studies conducted with Stem Pharm's proprietary neuro-immune organoid platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001062993-26-001567","json":"https://secwatch.observer/filing/0001062993-26-001567.json","markdown":"https://secwatch.observer/filing/0001062993-26-001567.md","text":"https://secwatch.observer/filing/0001062993-26-001567.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728328/000106299326001567/0001062993-26-001567-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728328/000106299326001567/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:22:49.916767+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}